Esperion Therapeutics (ESPR) Appoints Seth H.Z. Fischer to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
November 1, 2021 7:00 AM EDTANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders.
"On behalf of the Esperion team and our directors, I am very pleased to welcome Seth to the Esperion board. His deep operational and commercial expertise will be especially relevant during this exciting and transformative time for our Company, said Sheldon Koenig, president and chief executive officer of Esperion. Seth is a proven leader with a successful track record... More
